Literature DB >> 22075199

Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability.

Hyon Ju Park1, Prabha Ranganathan.   

Abstract

It is essential to be aware of both neoplastic and paraneoplastic vasculitides, vasculopathy, and hypercoagulability, considering the importance of an accurate diagnosis and timely treatment of the underlying malignancy. Characteristics such as the type of vasculitis, age, gender, atypical presentation, and lack of response to common therapies should prompt investigation for an occult malignancy, whereas vasculitis such as GPA require due malignancy vigilance given a significantly increased risk of malignancy at the time of diagnosis and in the following years. Vasculopathies are rarer than vasculitides, but are associated with specific malignancies and, in the context of such malignancies, should be kept in mind. Hypercoagulability is a well-documented neoplastic phenomenon with an increased risk of thrombosis in the setting of positive aPLs. Most neoplastic and paraneoplastic vascular syndromes require no specific treatment outside of treatment of the underlying malignancy. The two key exceptions are PACNS, because of its poor prognosis, and erythromelalgia, in which aspirin is an effective agent.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075199     DOI: 10.1016/j.rdc.2011.09.002

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  6 in total

1.  Adenocarcinoma of lung masquerading as systemic auto-immune disease.

Authors:  Kushal Naha; Sayali Thakare; G Vivek; Mukhyaprana Prabhu
Journal:  BMJ Case Rep       Date:  2012-06-14

Review 2.  Myelodysplasia and malignancy-associated vasculitis.

Authors:  Amir Agha; Helen Bateman; Ashley Sterrett; Joanne Valeriano-Marcet
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

Review 3.  Paraneoplastic musculoskeletal disorders: review and update for radiologists.

Authors:  Kimia Khalatbari Kani; Jack A Porrino; Michael E Mulligan; Felix S Chew
Journal:  Skeletal Radiol       Date:  2022-05-23       Impact factor: 2.199

4.  Inferior Vena Cava and Renal Vein Thrombosis Associated with Thymic Carcinoma.

Authors:  Vlad Teodor Berbecar; Roxana Jurubita; Marina Paraschiv; Bogdan Obrisca; Bogdan Sorohan; Gener Ismail
Journal:  Case Rep Med       Date:  2017-01-10

Review 5.  Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.

Authors:  Konstantinos Melissaropoulos; Kalliopi Klavdianou; Alexandra Filippopoulou; Fotini Kalofonou; Haralabos Kalofonos; Dimitrios Daoussis
Journal:  Int J Mol Sci       Date:  2020-05-11       Impact factor: 5.923

Review 6.  Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature.

Authors:  Víctor Albarrán; Jesús Chamorro; Diana Isabel Rosero; Cristina Saavedra; Ainara Soria; Alfredo Carrato; Pablo Gajate
Journal:  Front Pharmacol       Date:  2022-02-14       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.